|Friday, April 18, 2014
You are here: Home » Business » BioMarin Pharmaceutical (NASDAQ:BMRN) & DNDN Have A “Buy” And “Hold” Rating, Respectively: Consensus View

BioMarin Pharmaceutical (NASDAQ:BMRN) & DNDN Have A “Buy” And “Hold” Rating, Respectively: Consensus View 



On Friday, ARN reported that in a research note analysts at Wedbush reiterated its hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN)’s stock. Currently, they have $88.00 price target on the stock. Wedbush’s price objective indicates a potential rise of 14.36% from the stock’s earlier close.

Recently, BioMarin Pharmaceutical (NASDAQ:BMRN)’s stock has been weighed by a number of other analysts. On Wednesday, in a research note to investors, analysts at RBC Capital maintained a “buy” rating on company’s shares. Now, they have a $77.00 price objective on the stock. Separately, on Wednesday, in a research note to investors, analysts at William Blair maintained a “hold” rating on company’s shares. Now, they have a $88.00 price objective on the stock. Finally, on Wednesday, in a research note to investors, analysts at Stifel Nicolaus downgraded the company’s stock from a “buy” to a “hold” rating. Now, they set a $70.00 price objective on the stock. Eight investment analysts have given a hold rating and thirteen have rated as buy. The company has an average rating of “Buy” and an average price objective of $72.68.

TheFlyOnTheWall.com reported that in a research note issued to investors on Wednesday, Maxim Group upgraded the Dendreon Corp. (NASDAQ:DNDN)’s shares to a hold rating from a sell rating. The analysts called the move a valuation call.

Recently, Dendreon Corp. (NASDAQ:DNDN)’s stock has been commented by a number of other analysts. On Tuesday, in a research note to investors, analysts at Needham & Company maintained a positive rating on company’s shares. Separately, in a research note to investors on Monday, September 9th, analysts at R. F. Lafferty started coverage on company’s shares. They set $8.00 price objective on the stock, rating it as a buy. Finally, in a research note to investors on Wednesday, August 28th, analysts at RBC Capital cut their price target on company’s shares from $5.00 to $3.00. Now, they set a sell rating on the stock. Nine research analysts have given a sell rating to the stock, eight have rated the stock as hold and four have issued a buy rating to the company’s stock.  Currently, the stock has an average rating of Hold and a consensus price objective of $5.02.
Looking for the next Rising Stock? Many companies are often too expensive by the time they hit the news. Start looking early for undiscovered companies with huge potential and you can make 300%+ easily.

Read More: Find Out The Next Biggest Cannabis Play

Personal Capital help investors create an optimal portfolio based on your risk profile and help you save fees. Learn More by Clicking Here.

About the author: Kevin Sims

Editor Kevin Sims is markets editor for eFinanceHub. As a writer, Mr. Sims has contributed to books published by Harvard University Press and Universe Publishing, and has written for such periodicals as the Daily Beast, the Forward, and the Village Voice. Mr. Sims earned a Bachelor’s degree in Literature from University of Wisconsin-Madison in 2000 and a Master’s degree from New York University in Journalism in 2003. Contact Kevin via email at KSims@eFinanceHub.com.

Add a Comment

You must be logged in to post a comment.


Fatal error: Call to undefined function newsletter_withcross() in /home/efinance/public_html/wp-content/themes/local-news/localnews/single.php on line 14